Risk factor
Limited default risk
Profitability factor
Strong growth
About
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of BSLN.SW is 81 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell